Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research.
Alicia M DeLouizeGeeta N EickSana D KaramJames Josh SnodgrassPublished in: American journal of human biology : the official journal of the Human Biology Council (2021)
Despite advances in cancer medicine and research, invasive and potentially risky procedures such as biopsies, venous blood tests, imaging, colonoscopy, and pap smear tests are still primarily used for screening, staging, and assessing response to therapy. The development and interdisciplinary use of biomarkers from urine, feces, saliva, scent, and capillary blood collected with minimally invasive methods represents a potential opportunity for integration with biomarker analysis for cancers, both in clinical practice (e.g., in screening, treatment, and disease monitoring, and improved quality of life for patients) and population-based research (e.g., in epidemiology/public health, studies of social and environmental determinants, and evolutionary medicine). In this article, we review the scientific rationale, benefits, challenges, and potential opportunities for measuring cancer-related biomarkers in samples collected through minimally invasive methods.
Keyphrases
- minimally invasive
- public health
- papillary thyroid
- end stage renal disease
- clinical practice
- squamous cell
- robot assisted
- chronic kidney disease
- human health
- healthcare
- ejection fraction
- newly diagnosed
- clinical trial
- high resolution
- lymph node
- peritoneal dialysis
- prognostic factors
- mental health
- risk factors
- lymph node metastasis
- stem cells
- childhood cancer
- climate change
- photodynamic therapy
- risk assessment
- current status
- mesenchymal stem cells
- combination therapy
- ultrasound guided
- replacement therapy